CTXR News and Press, Citius Pharmaceuticals Inc. From 08/11/25

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Citius Pharmaceuticals Inc. (CTXR) is expected to report for Q3 2025

2025-08-10 18:45:14 ET Citius Pharmaceuticals, Inc. (CTXR) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 6.08%. The average open to low on the day of earnings was -4.74%. The average o...

2025-08-10 18:40:15 ET Citius Pharmaceuticals, Inc. (CTXR) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in CTXR stock price following earnings has averaged ±2.01% , with a median of 1....

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – More and more young women are getting diagnosed with cancer than ever before, causing many to sound the alarm about reduced funding for prevention and treatment. Pr...

Citius Oncology Announces Closing of $9.0 Million Public Offering PR Newswire CRANFORD, N.J. , July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Na...

2025-07-16 09:28:48 ET More on Citius Pharmaceuticals Cencora distribution deal boosts Citius shares Citius Pharmaceuticals slides on $15.8M securities offering Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius ...

Citius Oncology Announces Pricing of $9.0 Million Public Offering PR Newswire CRANFORD, N.J. , July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Na...

2025-07-15 10:17:08 ET Top-line Summary Read the full article on Seeking Alpha For further details see: Citius Oncology: Is A Lymphir Launch Coming Too Late?

2025-07-15 08:56:48 ET More on Citius Pharmaceuticals, Cencora, etc. Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript Cencora, Inc. 2025 Q2 - Results - Earnings Call Presentation ...